ANORMED TO GET $3 MILLION SHIRE PAYMENT

AnorMED Inc. said Monday it will receive a $3 million milestone payment from Shire Pharmaceuticals Group PLC, based on Shire's recent licensing approval in Britain to sell Fosrenol as a treatment for high phosphate levels in the blood, which occurs in patients undergoing dialysis as a result of chronic kidney failure.

MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=AP&Date=20060925&ID=6049827)